Retinitis Pigmentosa Treatment & Therapy Options in Turkey

What is retinitis pigmentosa?

Retinitis pigmentosa (RP) represents a group of genetic eye diseases where the retina gradually loses photoreceptor cells. This light-sensitive tissue at the back of the eye deteriorates progressively, causing vision loss that typically begins with night blindness.

The disease affects approximately 1 in 4,000 people worldwide, though prevalence varies by region. Symptoms often appear in childhood or early adulthood, progressing at different rates depending on the genetic mutation involved. Some patients experience rapid decline over years, while others maintain functional vision for decades with proper management.

Unlike age-related macular degeneration, RP affects the entire retina rather than just the central area. This means peripheral vision loss dominates early stages, making navigation in dim environments particularly challenging. The rod photoreceptors (responsible for night vision) are affected first, followed by cone photoreceptors (responsible for color and detail vision).

Retinitis pigmentosa (RP): Causes & complications

Retinitis pigmentosa is primarily a genetic disease transmitted through various inheritance patterns: autosomal recessive (most common, requiring mutations from both parents),autosomal dominant (one mutated gene from either parent),or X-linked (affecting males predominantly). Over 280 genes have been identified as causing RP, making genetic testing essential for accurate diagnosis and family counseling.

The genetic mutations disrupt proteins essential for photoreceptor function. Without proper protein synthesis, rod and cone cells cannot process light signals effectively, leading to cell death over time. This process, called photoreceptor degeneration, is irreversible once cells are lost, though slowing progression remains achievable.

Complications include cataracts (occurring in 40-50% of RP patients),cystoid macular edema (fluid accumulation in the macula affecting central vision),and secondary glaucoma. Psychological impact is significant, as progressive vision loss affects employment, independence, and quality of life. Early intervention with specialized medical care helps manage these complications effectively.

Diagnosis of retinitis pigmentosa in Turkey

Diagnosis requires comprehensive ophthalmologic evaluation combining clinical examination with advanced imaging. Turkish specialists begin with detailed patient history, family genetic background, and symptom timeline to establish disease progression patterns.

Essential diagnostic tests include electroretinography (ERG),which measures electrical responses of retinal cells to light stimuli. This test confirms photoreceptor dysfunction even before visible changes appear on examination. Optical coherence tomography (OCT) provides detailed cross-sectional images of retinal structure, revealing photoreceptor layer thinning and macular changes.

Visual field testing documents peripheral vision loss extent and progression rate. Genetic testing identifies specific mutations, enabling targeted therapy selection and accurate prognosis. Fundus photography documents retinal appearance, showing characteristic bone-spicule pigmentation patterns typical of advanced RP. These combined assessments guide personalized treatment planning and help predict disease trajectory over 5-10 years.

Treatment options for retinitis pigmentosa in Turkey

There is no cure for retinitis pigmentosa, so treatment focuses on confirming the diagnosis, monitoring progression and managing complications such as cataract and macular edema. Low-vision rehabilitation helps preserve independence.

Gene therapy is the only approved genetic treatment. Luxturna (voretigene neparvovec) targets confirmed biallelic RPE65 mutations, a small minority of RP cases, and is delivered by subretinal injection. Eligibility is confirmed by genetic testing, and availability and price in Turkey must be checked with the clinic before travelling.

Stem cell therapy for retinitis pigmentosa is experimental and not approved by regulators such as the FDA or EMA. Consider it only within regulated clinical trials, because unproven injections have caused serious complications, including permanent vision loss.

High-dose vitamin A is not routinely recommended and is only for selected adults under retina specialist supervision, as it can be harmful. High-dose vitamin E should be avoided because it may accelerate vision loss. Ask your ophthalmologist before taking any supplement.